Unibest

Pharmaceutical intermediates

IVOSIDENIB Intermediates

3 pharmaceutical intermediates for IVOSIDENIB. Indication: Leukemia, Myeloid, Acute; Bile Duct Neoplasm; Myelodysplastic Syndromes; Cholangiocarcinoma;.

提交项目All intermediates

About IVOSIDENIB

Originator
Agios Pharmaceuticals Inc
Indication
Leukemia, Myeloid, Acute; Bile Duct Neoplasm; Myelodysplastic Syndromes; Cholangiocarcinoma;
Approved Date
07/20/2018
DS/DP
06/21/2030

Available intermediates

3 intermediates currently listed for IVOSIDENIB. Request specifications, documentation or a quotation for any item below.

IVOSIDENIB intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1,1-difluoro-3-isocyanocyclobutane1355328-31-2//
3-Amino-5-fluoropyridine210169-05-4//
Amino-2,6-dichloro-5-fluoropyridine152840-65-8//

Other programs under I

Ibrutinib/ Zanubrutinib IguratimodImatinibImeglimin hydrochlorideIndacaterol MaleateInfigratinibIpatacopan HydrochlorideIpragliflozin

Building toward IVOSIDENIB?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →